298 related articles for article (PubMed ID: 17420693)
1. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease.
Matsumoto Y; Freund KB; Peiretti E; Cooney MJ; Ferrara DC; Yannuzzi LA
Retina; 2007; 27(4):426-31. PubMed ID: 17420693
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.
Rabena MD; Pieramici DJ; Castellarin AA; Nasir MA; Avery RL
Retina; 2007; 27(4):419-25. PubMed ID: 17420692
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
5. Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.
Yamaike N; Tsujikawa A; Sakamoto A; Ota M; Kotera Y; Miyamoto K; Kita M; Yoshimura N
Retina; 2009 Jun; 29(6):757-67. PubMed ID: 19289982
[TBL] [Abstract][Full Text] [Related]
6. Rebound of macular edema after intravitreal bevacizumab therapy in eyes with macular edema secondary to branch retinal vein occlusion.
Yasuda S; Kondo M; Kachi S; Ito Y; Terui T; Ueno S; Terasaki H
Retina; 2011 Jun; 31(6):1075-82. PubMed ID: 21478810
[TBL] [Abstract][Full Text] [Related]
7. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.
Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM
Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
Lim JW
Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
10. Comment of article by Matsumoto Y.
Campa C; D'Angelo S; Incorvaia C
Retina; 2008 May; 28(5):782; author reply 782-3. PubMed ID: 18463528
[No Abstract] [Full Text] [Related]
11. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
12. Treatment of branch retinal vein occlusion induced macular edema with bevacizumab.
Abegg M; Tappeiner C; Wolf-Schnurrbusch U; Barthelmes D; Wolf S; Fleischhauer J
BMC Ophthalmol; 2008 Sep; 8():18. PubMed ID: 18823536
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis.
Kondo M; Kondo N; Ito Y; Kachi S; Kikuchi M; Yasuma TR; Ota I; Kensaku M; Terasaki H
Retina; 2009 Oct; 29(9):1242-8. PubMed ID: 19672216
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.
Priglinger SG; Wolf AH; Kreutzer TC; Kook D; Hofer A; Strauss RW; Alge CS; Kunze C; Haritoglou C; Kampik A
Retina; 2007 Oct; 27(8):1004-12. PubMed ID: 18040236
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion.
Hung KH; Lee SM; Lee SY; Lee FL; Yang CS
J Ocul Pharmacol Ther; 2010 Feb; 26(1):85-90. PubMed ID: 20148661
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab for branch retinal vein occlusion.
Spandau U; Wickenhäuser A; Rensch F; Jonas J
Acta Ophthalmol Scand; 2007 Feb; 85(1):118-9. PubMed ID: 17244225
[No Abstract] [Full Text] [Related]
19. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2009; 29(10):1396-403. PubMed ID: 19898177
[TBL] [Abstract][Full Text] [Related]
20. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year.
Kriechbaum K; Prager F; Geitzenauer W; Benesch T; Schütze C; Simader C; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2415-21. PubMed ID: 19744723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
